Swiss drugmaker Roche (ROG.S) on Thursday outshone crosstown rival Novartis (NOVN.S) by boosting its 2018 sales outlook, helped by new medicines in a year when many feared patent expirations and cheaper copies would put growth at risk. Roche first-half sales rose 7 percent in constant currencies, topping the 5 percent rise Novartis reported last week. Its shares were 3 percent up by 0710 GMT, outperforming Novartis' 0.3 percent rise.
from Yahoo Finance https://yhoo.it/2v24aOr
No comments:
Post a Comment